Hosted on MSN1mon
4D Molecular price target lowered to $6 from $8 at Morgan Stanley
Morgan Stanley analyst Judah Frommer lowered the firm’s price target on 4D Molecular (FDMT) to $6 from $8 and keeps an Underweight rating on the shares after the company announced a pipeline ...
H.C. Wainwright maintains buy on 4D Molecular Therapeutics stock
H.C. Wainwright reaffirmed a Buy rating on shares of 4D Molecular Therapeutics (NASDAQ:FDMT) with a $36.00 price target. The stock, currently trading at $5.97, has seen significant volatility, with ...
ETF Daily News1mon
4D Molecular Therapeutics (NASDAQ:FDMT) Price Target Cut to $6.00 by Analysts at Morgan Stanley
4D Molecular Therapeutics (NASDAQ:FDMT – Free Report) had its price objective trimmed by Morgan Stanley from $8.00 to $6.00 in a report published on Monday,Benzinga reports.The brokerage ...